Published in J Clin Oncol on May 10, 2005
Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol (2008) 1.26
Resection of non-small cell lung cancers reverses tumor-induced gene expression changes in the peripheral immune system. Clin Cancer Res (2011) 1.24
Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications. Curr Pharm Des (2010) 1.23
MicroRNAs in the pathogenesis of Lung Cancer. J Thorac Oncol (2009) 1.17
The role of gene expression profiling in early-stage non-small cell lung cancer. J Thorac Dis (2010) 0.93
MALDI profiling of human lung cancer subtypes. PLoS One (2009) 0.93
Effects of common polymorphism rs11614913 in Hsa-miR-196a2 on lung cancer risk. PLoS One (2013) 0.87
A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas. Neoplasia (2010) 0.84
Cigarette-Smoke-Induced Dysregulation of MicroRNA Expression and Its Role in Lung Carcinogenesis. Pulm Med (2011) 0.79
Clinical Significance of Long Non-Coding RNA CASC8 rs10505477 Polymorphism in Lung Cancer Susceptibility, Platinum-Based Chemotherapy Response, and Toxicity. Int J Environ Res Public Health (2016) 0.77
Dietary D-glucarate effects on the biomarkers of inflammation during early post-initiation stages of benzo[a]pyrene-induced lung tumorigenesis in A/J mice. Oncol Lett (2010) 0.76
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis. Oncotarget (2016) 0.76
Effects of flavopiridol on critical regulation pathways of CD133high/CD44high lung cancer stem cells. Medicine (Baltimore) (2016) 0.75
Pulmonary squamous cell carcinoma and sorafenib. Clin Case Rep (2014) 0.75
Identifying the miRNA signature associated with survival time in patients with lung adenocarcinoma using miRNA expression profiles. Sci Rep (2017) 0.75
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol (2009) 1.10
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol (2003) 1.03
Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. J Clin Oncol (2007) 0.98
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Cancer (2012) 0.92
Summary of presentations from the 11th targeted therapies for lung cancer meeting: immunotherapy and vaccines for treatment of lung cancer. J Thorac Oncol (2011) 0.84
Cytochrome P450 expression (CYP) in non-small cell lung cancer. Front Biosci (2007) 0.82
Early stage lung cancer: progress in the last 40 years.. J Thorac Oncol (2014) 0.81
Molecular origins of lung cancer: prospects for personalized prevention and therapy. J Thorac Oncol (2010) 0.79
CYP7B1 Enzyme Deletion Impairs Reproductive Behaviors in Male Mice. Endocrinology (2015) 0.79
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. J Immunother (2007) 0.75